Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial

Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options. The IMbrave trail demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Fencer, Maria G., Davis, Catherine H., Liu, Jieqi, Galan, Mark A., Spencer, Kristen R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791267/
https://www.ncbi.nlm.nih.gov/pubmed/36541195
http://dx.doi.org/10.1177/23247096221129470
_version_ 1784859368579137536
author Fencer, Maria G.
Davis, Catherine H.
Liu, Jieqi
Galan, Mark A.
Spencer, Kristen R.
author_facet Fencer, Maria G.
Davis, Catherine H.
Liu, Jieqi
Galan, Mark A.
Spencer, Kristen R.
author_sort Fencer, Maria G.
collection PubMed
description Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options. The IMbrave trail demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants. Herein, we describe a case of disease control achieved using the IMbrave regimen in a patient with sarcomatoid hepatocellular carcinoma.
format Online
Article
Text
id pubmed-9791267
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-97912672022-12-27 Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial Fencer, Maria G. Davis, Catherine H. Liu, Jieqi Galan, Mark A. Spencer, Kristen R. J Investig Med High Impact Case Rep Case Report Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options. The IMbrave trail demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants. Herein, we describe a case of disease control achieved using the IMbrave regimen in a patient with sarcomatoid hepatocellular carcinoma. SAGE Publications 2022-12-21 /pmc/articles/PMC9791267/ /pubmed/36541195 http://dx.doi.org/10.1177/23247096221129470 Text en © 2022 American Federation for Medical Research https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Fencer, Maria G.
Davis, Catherine H.
Liu, Jieqi
Galan, Mark A.
Spencer, Kristen R.
Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial
title Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial
title_full Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial
title_fullStr Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial
title_full_unstemmed Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial
title_short Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial
title_sort disease control achieved using atezolizumab + bevacizumab in a patient with sarcomatoid hepatocellular carcinoma (shcc), a rare variant excluded from the imbrave150 trial
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791267/
https://www.ncbi.nlm.nih.gov/pubmed/36541195
http://dx.doi.org/10.1177/23247096221129470
work_keys_str_mv AT fencermariag diseasecontrolachievedusingatezolizumabbevacizumabinapatientwithsarcomatoidhepatocellularcarcinomashccararevariantexcludedfromtheimbrave150trial
AT daviscatherineh diseasecontrolachievedusingatezolizumabbevacizumabinapatientwithsarcomatoidhepatocellularcarcinomashccararevariantexcludedfromtheimbrave150trial
AT liujieqi diseasecontrolachievedusingatezolizumabbevacizumabinapatientwithsarcomatoidhepatocellularcarcinomashccararevariantexcludedfromtheimbrave150trial
AT galanmarka diseasecontrolachievedusingatezolizumabbevacizumabinapatientwithsarcomatoidhepatocellularcarcinomashccararevariantexcludedfromtheimbrave150trial
AT spencerkristenr diseasecontrolachievedusingatezolizumabbevacizumabinapatientwithsarcomatoidhepatocellularcarcinomashccararevariantexcludedfromtheimbrave150trial

Ejemplares similares